Bharat Biotech seeks DCGI nod for study of intra-nasal COVID vaccine as booster dose
New Delhi: Indian vaccine maker Bharat Biotech said on Monday it has submitted an application to the country's drug regulator to conduct a late-stage trial for a booster dose of its intranasal COVID-19 vaccine.Indian COVID-19 vaccine makers are lobbying the government to authorise boosters as supplies have far outstripped demand, but the health ministry said there is no immediate plan to...
New Delhi: Indian vaccine maker Bharat Biotech said on Monday it has submitted an application to the country's drug regulator to conduct a late-stage trial for a booster dose of its intranasal COVID-19 vaccine.
Key Attributes of intranasal COVID vaccine:
. An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.
. Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.
Covaxin, the company's COVID-19 vaccine already approved for emergency-use approval in the county, is administered through an injection.
Coronavirus cases in India have fallen sharply since a devastating second wave earlier this year. The South Asian nation has detected over 100 cases of the Omicron variant so far.
Bharat Biotech International Limited is an Indian multinational biotechnology company headquartered in Genome Valley, Turakapally, Hyderabad. The company was founded by Krishna Ella in 1996.